APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars Insulin

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Biosimilars Insulin Industry Growth and Trends Forecast to 2032

Report ID 173970980122 December 202592 pages

Choose your research edition.

Industry ResearchBiosimilars Insulin Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars Insulin Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Biosimilars Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars Insulin Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars Insulin Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Biosimilars Insulin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Biosimilars Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Biosimilars Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biosimilars Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biosimilars Insulin include Tonghua Dongbao, Sanofi, United Laboratories, Eli Lilly, Gan & Lee Pharmaceuticals, Boehringer Ingelheim and Biocon/Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Biosimilars Insulin market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Biosimilars Insulin market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biosimilars Insulin market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biosimilars Insulin.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Biosimilars Insulin market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Biosimilars Insulin Market by Company

Tonghua Dongbao

Sanofi

United Laboratories

Eli Lilly

Gan & Lee Pharmaceuticals

Boehringer Ingelheim

Biocon/Mylan

Biosimilars Insulin Segment by Type

Insulin Aspart

Insulin Lispro

Insulin Glargine

Other

Biosimilars Insulin Segment by Application

Type I Diabetes

Type II Diabetes

Biosimilars Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilars Insulin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Biosimilars Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Insulin Aspart Table 2. Major Company of Insulin Lispro Table 3. Major Company of Insulin Glargine Table 4. Major Company of Other Table 5. Global Biosimilars Insulin Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Biosimilars Insulin Sales by Type (2021-2026) & (k units) Table 7. Global Biosimilars Insulin Sales Market Share in Volume by Type (2021-2026) Table 8. Global Biosimilars Insulin Sales by Type (2021-2026) & (US$ Million) Table 9. Global Biosimilars Insulin Sales Market Share in Value by Type (2021-2026) Table 10. Global Biosimilars Insulin Price by Type (2021-2026) & (US$/unit) Table 11. Global Biosimilars Insulin Sales by Type (2027-2032) & (k units) Table 12. Global Biosimilars Insulin Sales Market Share in Volume by Type (2027-2032) Table 13. Global Biosimilars Insulin Sales by Type (2027-2032) & (US$ Million) Table 14. Global Biosimilars Insulin Sales Market Share in Value by Type (2027-2032) Table 15. Global Biosimilars Insulin Price by Type (2027-2032) & (US$/unit) Table 16. North America Biosimilars Insulin Sales by Type (2021-2026) & (k units) Table 17. North America Biosimilars Insulin Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Biosimilars Insulin Sales by Type (2021-2026) & (k units) Table 19. Europe Biosimilars Insulin Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Biosimilars Insulin Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Biosimilars Insulin Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Biosimilars Insulin Sales by Type (2021-2026) & (k units) Table 23. Latin America Biosimilars Insulin Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Biosimilars Insulin Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Biosimilars Insulin Sales by Type (2021-2026) & (US$ Million) Table 26. Biosimilars Insulin Industry Trends Table 27. Biosimilars Insulin Industry Drivers Table 28. Biosimilars Insulin Industry Opportunities and Challenges Table 29. Biosimilars Insulin Industry Restraints Table 30. Global Biosimilars Insulin Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Biosimilars Insulin Revenue Market Share by Company (2021-2026) Table 32. Global Biosimilars Insulin Sales by Company (2021-2026) & (k units) Table 33. Global Biosimilars Insulin Sales Share by Company (2021-2026) Table 34. Global Biosimilars Insulin Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Biosimilars Insulin Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Biosimilars Insulin Major Company Production Sites and Headquarters Table 37. Global Biosimilars Insulin Company, Product Type & Application Table 38. Global Biosimilars Insulin Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Biosimilars Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Biosimilars Insulin Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Biosimilars Insulin Sales by Region (2021-2026) & (k units) Table 43. Global Biosimilars Insulin Sales Market Share in Volume by Region (2021-2026) Table 44. Global Biosimilars Insulin Sales by Region (2021-2026) & (US$ Million) Table 45. Global Biosimilars Insulin Sales Market Share in Value by Region (2021-2026) Table 46. Global Biosimilars Insulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Biosimilars Insulin Sales by Region (2027-2032) & (k units) Table 48. Global Biosimilars Insulin Sales Market Share in Volume by Region (2027-2032) Table 49. Global Biosimilars Insulin Sales by Region (2027-2032) & (US$ Million) Table 50. Global Biosimilars Insulin Sales Market Share in Value by Region (2027-2032) Table 51. Global Biosimilars Insulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Biosimilars Insulin Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Biosimilars Insulin Sales by Application (2021-2026) & (k units) Table 54. Global Biosimilars Insulin Sales Market Share in Volume by Application (2021-2026) Table 55. Global Biosimilars Insulin Sales by Application (2021-2026) & (US$ Million) Table 56. Global Biosimilars Insulin Sales Market Share in Value by Application (2021-2026) Table 57. Global Biosimilars Insulin Price by Application (2021-2026) & (US$/unit) Table 58. Global Biosimilars Insulin Sales by Application (2027-2032) & (k units) Table 59. Global Biosimilars Insulin Sales Market Share in Volume by Application (2027-2032) Table 60. Global Biosimilars Insulin Sales by Application (2027-2032) & (US$ Million) Table 61. Global Biosimilars Insulin Sales Market Share in Value by Application (2027-2032) Table 62. Global Biosimilars Insulin Price by Application (2027-2032) & (US$/unit) Table 63. North America Biosimilars Insulin Sales by Application (2021-2026) & (k units) Table 64. North America Biosimilars Insulin Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Biosimilars Insulin Sales by Application (2021-2026) & (k units) Table 66. Europe Biosimilars Insulin Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Biosimilars Insulin Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Biosimilars Insulin Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Biosimilars Insulin Sales by Application (2021-2026) & (k units) Table 70. Latin America Biosimilars Insulin Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Biosimilars Insulin Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Biosimilars Insulin Sales by Application (2021-2026) & (US$ Million) Table 73. Tonghua Dongbao Company Information Table 74. Tonghua Dongbao Business Overview Table 75. Tonghua Dongbao Biosimilars Insulin Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Tonghua Dongbao Biosimilars Insulin Product Portfolio Table 77. Tonghua Dongbao Recent Development Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi Biosimilars Insulin Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Sanofi Biosimilars Insulin Product Portfolio Table 82. Sanofi Recent Development Table 83. United Laboratories Company Information Table 84. United Laboratories Business Overview Table 85. United Laboratories Biosimilars Insulin Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. United Laboratories Biosimilars Insulin Product Portfolio Table 87. United Laboratories Recent Development Table 88. Eli Lilly Company Information Table 89. Eli Lilly Business Overview Table 90. Eli Lilly Biosimilars Insulin Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Eli Lilly Biosimilars Insulin Product Portfolio Table 92. Eli Lilly Recent Development Table 93. Gan & Lee Pharmaceuticals Company Information Table 94. Gan & Lee Pharmaceuticals Business Overview Table 95. Gan & Lee Pharmaceuticals Biosimilars Insulin Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Gan & Lee Pharmaceuticals Biosimilars Insulin Product Portfolio Table 97. Gan & Lee Pharmaceuticals Recent Development Table 98. Boehringer Ingelheim Company Information Table 99. Boehringer Ingelheim Business Overview Table 100. Boehringer Ingelheim Biosimilars Insulin Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Boehringer Ingelheim Biosimilars Insulin Product Portfolio Table 102. Boehringer Ingelheim Recent Development Table 103. Biocon/Mylan Company Information Table 104. Biocon/Mylan Business Overview Table 105. Biocon/Mylan Biosimilars Insulin Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Biocon/Mylan Biosimilars Insulin Product Portfolio Table 107. Biocon/Mylan Recent Development Table 108. North America Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 109. North America Biosimilars Insulin Sales by Country (2021-2026) & (k units) Table 110. North America Biosimilars Insulin Sales Market Share by Country (2021-2026) Table 111. North America Biosimilars Insulin Sales Forecast by Country (2027-2032) & (k units) Table 112. North America Biosimilars Insulin Sales Market Share Forecast by Country (2027-2032) Table 113. North America Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. North America Biosimilars Insulin Market Size by Country (2021-2026) & (US$ Million) Table 115. North America Biosimilars Insulin Market Share by Country (2021-2026) Table 116. North America Biosimilars Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. North America Biosimilars Insulin Market Share Forecast by Country (2027-2032) Table 118. Europe Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 119. Europe Biosimilars Insulin Sales by Country (2021-2026) & (k units) Table 120. Europe Biosimilars Insulin Sales Market Share by Country (2021-2026) Table 121. Europe Biosimilars Insulin Sales Forecast by Country (2027-2032) & (k units) Table 122. Europe Biosimilars Insulin Sales Market Share Forecast by Country (2027-2032) Table 123. Europe Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Europe Biosimilars Insulin Market Size by Country (2021-2026) & (US$ Million) Table 125. Europe Biosimilars Insulin Market Share by Country (2021-2026) Table 126. Europe Biosimilars Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Europe Biosimilars Insulin Market Share Forecast by Country (2027-2032) Table 128. Asia-Pacific Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 129. Asia-Pacific Biosimilars Insulin Sales by Country (2021-2026) & (k units) Table 130. Asia-Pacific Biosimilars Insulin Sales Market Share by Country (2021-2026) Table 131. Asia-Pacific Biosimilars Insulin Sales Forecast by Country (2027-2032) & (k units) Table 132. Asia-Pacific Biosimilars Insulin Sales Market Share Forecast by Country (2027-2032) Table 133. Asia-Pacific Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Asia-Pacific Biosimilars Insulin Market Size by Country (2021-2026) & (US$ Million) Table 135. Asia-Pacific Biosimilars Insulin Market Share by Country (2021-2026) Table 136. Asia-Pacific Biosimilars Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Asia-Pacific Biosimilars Insulin Market Share Forecast by Country (2027-2032) Table 138. Latin America Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 139. Latin America Biosimilars Insulin Sales by Country (2021-2026) & (k units) Table 140. Latin America Biosimilars Insulin Sales Market Share by Country (2021-2026) Table 141. Latin America Biosimilars Insulin Sales Forecast by Country (2027-2032) & (k units) Table 142. Latin America Biosimilars Insulin Sales Market Share Forecast by Country (2027-2032) Table 143. Latin America Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Latin America Biosimilars Insulin Market Size by Country (2021-2026) & (US$ Million) Table 145. Latin America Biosimilars Insulin Market Share by Country (2021-2026) Table 146. Latin America Biosimilars Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Latin America Biosimilars Insulin Market Share Forecast by Country (2027-2032) Table 148. Middle East and Africa Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 149. Middle East and Africa Biosimilars Insulin Sales by Country (2021-2026) & (k units) Table 150. Middle East and Africa Biosimilars Insulin Sales Market Share by Country (2021-2026) Table 151. Middle East and Africa Biosimilars Insulin Sales Forecast by Country (2027-2032) & (k units) Table 152. Middle East and Africa Biosimilars Insulin Sales Market Share Forecast by Country (2027-2032) Table 153. Middle East and Africa Biosimilars Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Middle East and Africa Biosimilars Insulin Market Size by Country (2021-2026) & (US$ Million) Table 155. Middle East and Africa Biosimilars Insulin Market Share by Country (2021-2026) Table 156. Middle East and Africa Biosimilars Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Middle East and Africa Biosimilars Insulin Market Share Forecast by Country (2027-2032) Table 158. Key Raw Materials Table 159. Raw Materials Key Suppliers Table 160. Biosimilars Insulin Distributors List Table 161. Biosimilars Insulin Customers List Table 162. Research Programs/Design for This Report Table 163. Authors List of This Report Table 164. Secondary Sources Table 165. Primary Sources List of Figures Figure 1. Biosimilars Insulin Image Figure 2. Global Biosimilars Insulin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilars Insulin Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilars Insulin Sales (2021-2032) & (k units) Figure 5. Insulin Aspart Image Figure 6. Global Insulin Aspart Sales YoY Growth (2021-2032) & (k units) Figure 7. Insulin Lispro Image Figure 8. Global Insulin Lispro Sales YoY Growth (2021-2032) & (k units) Figure 9. Insulin Glargine Image Figure 10. Global Insulin Glargine Sales YoY Growth (2021-2032) & (k units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Biosimilars Insulin Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Biosimilars Insulin Market Share by Type 2025 VS 2032 Figure 15. North America Biosimilars Insulin Sales Market Share in Volume by Type in 2025 Figure 16. North America Biosimilars Insulin Sales Market Share in Value by Type in 2025 Figure 17. Europe Biosimilars Insulin Sales Market Share in Volume by Type in 2025 Figure 18. Europe Biosimilars Insulin Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Biosimilars Insulin Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Biosimilars Insulin Sales Market Share in Value by Type in 2025 Figure 21. Latin America Biosimilars Insulin Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Biosimilars Insulin Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Biosimilars Insulin Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Biosimilars Insulin Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Biosimilars Insulin Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Type I Diabetes Image Figure 28. Global Type I Diabetes Sales YoY Growth (2021-2032) & (k units) Figure 29. Type II Diabetes Image Figure 30. Global Type II Diabetes Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Biosimilars Insulin Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Biosimilars Insulin Market Share by Application 2025 VS 2032 Figure 33. North America Biosimilars Insulin Sales Market Share in Volume by Application in 2025 Figure 34. North America Biosimilars Insulin Sales Market Share in Value by Application in 2025 Figure 35. Europe Biosimilars Insulin Sales Market Share in Volume by Application in 2025 Figure 36. Europe Biosimilars Insulin Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Biosimilars Insulin Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Biosimilars Insulin Sales Market Share in Value by Application in 2025 Figure 39. Latin America Biosimilars Insulin Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Biosimilars Insulin Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Biosimilars Insulin Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Biosimilars Insulin Sales Market Share in Value by Application in 2025 Figure 43. North America Biosimilars Insulin Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Biosimilars Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Biosimilars Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Biosimilars Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Biosimilars Insulin Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Biosimilars Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Biosimilars Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Biosimilars Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Biosimilars Insulin Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Biosimilars Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Biosimilars Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Biosimilars Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Biosimilars Insulin Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Biosimilars Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Biosimilars Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Biosimilars Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Biosimilars Insulin Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Biosimilars Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Biosimilars Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Biosimilars Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Biosimilars Insulin Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Biosimilars Insulin Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin Aspart
  • Insulin Lispro
  • Insulin Glargine
  • Other
Applications
  • Type I Diabetes
  • Type II Diabetes
Companies covered
  • Tonghua Dongbao
  • Sanofi
  • United Laboratories
  • Eli Lilly
  • Gan & Lee Pharmaceuticals
  • Boehringer Ingelheim
  • Biocon/Mylan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biosimilars Insulin Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Biosimilars Insulin Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Biosimilars Insulin Market by Type
  6. 1.3.1 Insulin Aspart
  7. 1.3.2 Insulin Lispro
  8. 1.3.3 Insulin Glargine
  9. 1.3.4 Other
  10. 1.4 Global Biosimilars Insulin Market Size by Type
  11. 1.4.1 Global Biosimilars Insulin Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Biosimilars Insulin Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Biosimilars Insulin Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Biosimilars Insulin Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Biosimilars Insulin Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Biosimilars Insulin Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Biosimilars Insulin Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Biosimilars Insulin Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Biosimilars Insulin Industry Trends
  2. 2.2 Biosimilars Insulin Industry Drivers
  3. 2.3 Biosimilars Insulin Industry Opportunities and Challenges
  4. 2.4 Biosimilars Insulin Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Biosimilars Insulin Revenue (2021-2026)
  2. 3.2 Global Top Players by Biosimilars Insulin Sales (2021-2026)
  3. 3.3 Global Top Players by Biosimilars Insulin Price (2021-2026)
  4. 3.4 Global Biosimilars Insulin Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilars Insulin Major Company Production Sites & Headquarters
  6. 3.6 Global Biosimilars Insulin Company, Product Type & Application
  7. 3.7 Global Biosimilars Insulin Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilars Insulin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilars Insulin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilars Insulin Tier 1, Tier 2, and Tier 3
4 Biosimilars Insulin Regional Status and Outlook
  1. 4.1 Global Biosimilars Insulin Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Biosimilars Insulin Historic Market Size by Region
  3. 4.2.1 Global Biosimilars Insulin Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Biosimilars Insulin Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Biosimilars Insulin Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Biosimilars Insulin Forecasted Market Size by Region
  7. 4.3.1 Global Biosimilars Insulin Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Biosimilars Insulin Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Biosimilars Insulin Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Biosimilars Insulin by Application
  1. 5.1 Biosimilars Insulin Market by Application
  2. 5.1.1 Type I Diabetes
  3. 5.1.2 Type II Diabetes
  4. 5.2 Global Biosimilars Insulin Market Size by Application
  5. 5.2.1 Global Biosimilars Insulin Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Biosimilars Insulin Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Biosimilars Insulin Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Biosimilars Insulin Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Biosimilars Insulin Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Biosimilars Insulin Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Biosimilars Insulin Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Biosimilars Insulin Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Tonghua Dongbao
  2. 6.1.1 Tonghua Dongbao Company Information
  3. 6.1.2 Tonghua Dongbao Business Overview
  4. 6.1.3 Tonghua Dongbao Biosimilars Insulin Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Tonghua Dongbao Biosimilars Insulin Product Portfolio
  6. 6.1.5 Tonghua Dongbao Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Biosimilars Insulin Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Biosimilars Insulin Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 United Laboratories
  14. 6.3.1 United Laboratories Company Information
  15. 6.3.2 United Laboratories Business Overview
  16. 6.3.3 United Laboratories Biosimilars Insulin Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 United Laboratories Biosimilars Insulin Product Portfolio
  18. 6.3.5 United Laboratories Recent Developments
  19. 6.4 Eli Lilly
  20. 6.4.1 Eli Lilly Company Information
  21. 6.4.2 Eli Lilly Business Overview
  22. 6.4.3 Eli Lilly Biosimilars Insulin Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Eli Lilly Biosimilars Insulin Product Portfolio
  24. 6.4.5 Eli Lilly Recent Developments
  25. 6.5 Gan & Lee Pharmaceuticals
  26. 6.5.1 Gan & Lee Pharmaceuticals Company Information
  27. 6.5.2 Gan & Lee Pharmaceuticals Business Overview
  28. 6.5.3 Gan & Lee Pharmaceuticals Biosimilars Insulin Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Gan & Lee Pharmaceuticals Biosimilars Insulin Product Portfolio
  30. 6.5.5 Gan & Lee Pharmaceuticals Recent Developments
  31. 6.6 Boehringer Ingelheim
  32. 6.6.1 Boehringer Ingelheim Company Information
  33. 6.6.2 Boehringer Ingelheim Business Overview
  34. 6.6.3 Boehringer Ingelheim Biosimilars Insulin Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Boehringer Ingelheim Biosimilars Insulin Product Portfolio
  36. 6.6.5 Boehringer Ingelheim Recent Developments
  37. 6.7 Biocon/Mylan
  38. 6.7.1 Biocon/Mylan Company Information
  39. 6.7.2 Biocon/Mylan Business Overview
  40. 6.7.3 Biocon/Mylan Biosimilars Insulin Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Biocon/Mylan Biosimilars Insulin Product Portfolio
  42. 6.7.5 Biocon/Mylan Recent Developments
7 North America by Country
  1. 7.1 North America Biosimilars Insulin Sales by Country
  2. 7.1.1 North America Biosimilars Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Biosimilars Insulin Sales by Country (2021-2026)
  4. 7.1.3 North America Biosimilars Insulin Sales Forecast by Country (2027-2032)
  5. 7.2 North America Biosimilars Insulin Market Size by Country
  6. 7.2.1 North America Biosimilars Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Biosimilars Insulin Market Size by Country (2021-2026)
  8. 7.2.3 North America Biosimilars Insulin Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Biosimilars Insulin Sales by Country
  2. 8.1.1 Europe Biosimilars Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Biosimilars Insulin Sales by Country (2021-2026)
  4. 8.1.3 Europe Biosimilars Insulin Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Biosimilars Insulin Market Size by Country
  6. 8.2.1 Europe Biosimilars Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Biosimilars Insulin Market Size by Country (2021-2026)
  8. 8.2.3 Europe Biosimilars Insulin Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Biosimilars Insulin Sales by Country
  2. 9.1.1 Asia-Pacific Biosimilars Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Biosimilars Insulin Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Biosimilars Insulin Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Biosimilars Insulin Market Size by Country
  6. 9.2.1 Asia-Pacific Biosimilars Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Biosimilars Insulin Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Biosimilars Insulin Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Biosimilars Insulin Sales by Country
  2. 10.1.1 South America Biosimilars Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Biosimilars Insulin Sales by Country (2021-2026)
  4. 10.1.3 South America Biosimilars Insulin Sales Forecast by Country (2027-2032)
  5. 10.2 South America Biosimilars Insulin Market Size by Country
  6. 10.2.1 South America Biosimilars Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Biosimilars Insulin Market Size by Country (2021-2026)
  8. 10.2.3 South America Biosimilars Insulin Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Biosimilars Insulin Sales by Country
  2. 11.1.1 Middle East and Africa Biosimilars Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Biosimilars Insulin Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Biosimilars Insulin Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Biosimilars Insulin Market Size by Country
  6. 11.2.1 Middle East and Africa Biosimilars Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Biosimilars Insulin Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Biosimilars Insulin Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Biosimilars Insulin Value Chain Analysis
  2. 12.1.1 Biosimilars Insulin Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Biosimilars Insulin Production Mode & Process
  7. 12.2 Biosimilars Insulin Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Biosimilars Insulin Distributors
  10. 12.2.3 Biosimilars Insulin Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst